Cabezón, M., Malinverni, R., Bargay, J., Xicoy, B., Marcé, S., Garrido, A., . . . Zamora, L. (2021). Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival. Clin Epigenetics.
Čikaški stil citiranjaCabezón, M., et al. "Different Methylation Signatures At Diagnosis in Patients With High-risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Predict Azacitidine Response and Longer Survival." Clin Epigenetics 2021.
MLA način citiranjaCabezón, M., et al. "Different Methylation Signatures At Diagnosis in Patients With High-risk Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia Predict Azacitidine Response and Longer Survival." Clin Epigenetics 2021.